Epidemiology of Acromegaly: Review of population studies by Lavrentaki, A et al.
 
 
Epidemiology of Acromegaly: Review of population
studies
Lavrentaki, A; Karavitaki, Niki; Paluzzi, A; Wass, John A H
DOI:
10.1007/s11102-016-0754-x
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Lavrentaki, A, Karavitaki, N, Paluzzi, A & Wass, JAH 2017, 'Epidemiology of Acromegaly: Review of population
studies', Pituitary, vol. 20, no. 1, pp. 4–9. https://doi.org/10.1007/s11102-016-0754-x
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Epidemiology of acromegaly: review of population studies
Aikaterini Lavrentaki1 • Alessandro Paluzzi2 • John A. H. Wass3 • Niki Karavitaki4,5
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Acromegaly is a rare condition necessitating
large population studies for the generation of reliable epi-
demiological data. In this review, we systematically anal-
ysed the epidemiological profile of this condition based on
recently published population studies from various geo-
graphical areas. The total prevalence ranges between 2.8
and 13.7 cases per 100,000 people and the annual incidence
rates range between 0.2 and 1.1 cases/100,000 people. The
median age at diagnosis is in the fifth decade of life with a
median diagnostic delay of 4.5–5 years. Acral enlargement
and coarse facial features are the most commonly described
clinical manifestations. At the time of detection, most of
the tumors are macroadenomas possibly relating to diag-
nostic delays and posing challenges in the surgical man-
agement. Increased awareness of acromegaly amongst the
medical community is of major importance aiming to
reduce the adverse sequelae of late diagnosis and treat-
ment, improve patient outcomes and, hopefully, reduce the
burden on the health care system.
Keywords Acromegaly  Epidemiology  Prevalence 
Incidence
Introduction
Acromegaly is a rare condition characterized by growth
hormone (GH) excess and elevated Insulin-like growth
factor 1 (IGF-I) levels attributed in the vast majority of
cases, to a pituitary adenoma. Mortality is high in uncon-
trolled disease and adequate biochemical control may
restore it to normal [1].
The presentation of acromegaly can be insidious and
despite the advances in the field, there are significant
diagnostic delays with adverse sequelae on the prog-
nosis of the patients. The recently published Endocrine
Society clinical practice guidelines suggest screening
for acromegaly by measurement of IGF-I in patients
with typical clinical manifestations, but also in those
who lack the typical clinical picture and have several
associated conditions (sleep apnea syndrome, type 2
diabetes mellitus, debilitating arthritis, carpal tunnel
syndrome, hyperhidrosis, and hypertension) [2]. The
impact of this approach on the prevalence and incidence
rates of acromegaly in the future remains to be
elucidated.
Accurate and up-to-date epidemiological data on acro-
megaly are of major importance for describing patterns of
disease and generating hypotheses on causal factors, for
assessing the impact of this condition and its co-morbidi-
ties on patients, families and the community, for evaluating
the burden of acromegaly on the health care system and for
providing guidance on optimal allocation of resources
(clinical and research) which will ultimately lead to
improvement of patient outcomes.
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In this review, we will systematically analyse the epi-
demiological profile of acromegaly based on recently
published population studies from various geographical
areas. Data from cancer registries or isolated tertiary
referral centres will not be assessed; the former tend to
suffer from under-reporting of benign tumours including
pituitary adenomas and the latter are affected by selection
bias and wide variations in the referral patterns across the
world.
Epidemiology of acromegaly
The population studies assessing the epidemiology of
acromegaly are shown in Table 1.
Details of populations studied
Most of the published population studies have been con-
ducted in Europe. Fernandez et al. [3] performed a com-
munity based cross-sectional study through a computer
database search in fourteen General Practice surgeries
covering the urban and rural areas of Banbury (Oxford,
UK). Daly et al. [4] completed a cross-sectional, case-
finding study covering three regions in the Province of
Liege, Belgium. The patients were identified by general
practitioners and relevant specialists working in public/
private practice and further information was sought from
hospital case files or other relevant clinical records.
Tjornstrand et al. [5] identified patients from the Swedish
Pituitary Registry and medical records from six hospitals in
a county of western Sweden. Agustsson et al. [6] performed
a nationwide population study in Iceland and information
was obtained from medical records at the National
University Hospital, three district hospitals, all privately
practicing endocrinologists and gynaecologists in the
country, all radiology departments in Iceland, the Icelandic
Cancer Registry, the department of pathology and the Ice-
landic Heart Association. Hoskuldsdottir et al. [7] collected
data from the medical records at the National University
Hospital in Iceland, the largest hospital out of the capital,
the largest private outpatient clinic in Iceland and from all
endocrinologists treating adult patients in the country.
Raappana et al. [8] obtained information from Oulu
University Hospital in which the great majority of patients
with pituitary tumor from the four northernmost provinces
of Finland are referred. Dal et al. [9] covered the entire
population of Denmark and obtained data from the Danish
National Patient Registry, the Danish Civil Registration
System and the Danish Register of Causes of Death. Bex
et al. [10] collected information on patients with acrome-
galy through a nationwide survey involving all endocri-
nologists managing patients with pituitary disorders in
Belgium and the Grand Duchy of Luxembourg (the
University Hospital of Liege and some local centers did not
take part). Mestron et al. [11] analyzed data from the
Spanish acromegaly registry in which patients were vol-
untarily registered by the managing physicians. Gruppetta
Table 1 Prevalence, incidence and age at diagnosis of acromegaly in population studies
Reference Population
covered
Prevalence
(per 100,000)
Annual incidence
(per 100,000)
Age at diagnosis (years)
Median (range)
Total Males Females Total Males Females Total Males Females
Fernandez et al. [3] 81,449 8.6 4.9 3.7 NA NA NA 47 (30–63) 48.5 (30–52) 45 (39–63)
Daly et al. [4] 71,972 12.5 8.3 4.2 NA NA NA 47 (17–65) 41 (19–65) 56 (17–63)
Tjornstrand et al. [5] 1,590,640 3.3 1.7 1.6 0.4 0.4 0..4 NA NA NA
Agustsson et al. [6] 321,857 13.7 9.0 4.7 NA 0.8 0.4 45 (4–83) 45.0 (15–83) 44 (4–75)
Hoskuldsdottir
et al. [7]
316,075 13.3 NA NA 0.8 NA NA 44.5a (24.5–49.7) NA NA
Raappana et al. [8] 722,000 –
733,000
NA NA NA 0.3 0.4 0.3 40.5 (12–69) 41 38
Dal et al. [9] 5,534,738 8.5 NA NA 0.4 NA NA 48.7a (47.2–50.1) NA NA
Bex et al. [10] 10,850,000 4 NA NA 0.2 NA NA NA 42 (8–81) 46 (17–80)
Mestron et al. [11] Population of
Spain in 2001
3.4 NA NA 0.2 NA NA 45a NA NA
Gruppetta et al. [12] 417,608 12.4 10.6 14.3 0.3 0.2 0.4 44 (19–69) 36.5 (19–69) 49.5 (28–68)
Burton et al. [13] 50,170,946 7.8 7.7 7.7 1.1 1.0 1.2 41a NA NA
Kwon et al. [14] 48,456.369 2.8 1.3 1.5 0.4 NA NA 44.1a 42.2a 45.5a
NA not available
a Mean
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et al. [12] carried out a thorough search for patients with
pituitary adenoma in the central hospital registries covering
the Maltese islands. In the Burton et al. [13] study, the
source population was derived from a large health insur-
ance database which contains medical and pharmacy
claims, and enrollment information from a geographically
diverse group of health plans in the USA. The main limi-
tation of this study is that only cases with a related medical
claim were captured leading to possible underestimation of
true prevalence. Finally, Kwon et al. [14], in a nationwide
survey in South Korea selected 74 secondary and tertiary
care hospitals where patients with acromegaly were diag-
nosed or treated by both endocrinologists and
neurosurgeons.
In the above studies, the sources of information used
tend to be extensive and may be sufficient for the iden-
tification of the majority of the relevant cases. However,
the impact of each national health system, the referral
pathways and policies, the accuracy of reporting/register-
ing patients in national databases and the extend of
involvement of the private sector in the diagnosis and
management of subjects with acromegaly need to be taken
into account.
Prevalence, incidence, sex distribution and age
at diagnosis
The total prevalence ranges between 2.8 and 13.7 cases per
100,000 people [3–14]. The highest rates have been
reported in two studies covering Iceland [6, 7] and in one
from the Maltese islands [12], whereas the lowest has been
found by Kwon et al. [14], Tjornstrand et al. [5] and
Mestron et al. [11]. Notably, the last two studies obtained
information from the Swedish Pituitary Registry and the
Spanish acromegaly registry, respectively, and the possi-
bility of under-reporting cannot be excluded. It should be
also pointed out that the two studies from Iceland [6, 7]
cover the same population and have a significant overlap in
the sources of their data; this could sway the overall results
and they should not be considered as independent from
each other. In most studies, there is a rather equal distri-
bution of prevalence between males and females, with the
exception of Daly et al. [4] and Agustsson et al. [6], in
which men showed prevalence rates twice as high as those
of women.
The incidence rates range between 0.2 and 1.1 cases/
100,000 people and the very small numbers make it diffi-
cult to reach conclusions for potential differences between
the sexes (males: 0.2–1.0/100,000/year and females
0.3–1.2/100,000/year) [5–14].
Previously published studies (between 1980 and 2001)
have reported prevalence between 3.8 and 6.9/100,000 and
incidence rates between 0.28 and 0.4/100,000 [15–19]. T
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The higher rates of the contemporary studies may be
attributed to the methodology used (source of data: pop-
ulation vs tertiary referral centres, intensive case searching
approaches), to the increased awareness of pituitary dis-
ease and the advances in the diagnostic tools, to the fact
that affected patients may seek medical attention earlier in
the last years or they may reflect a true increase in the
prevalence.
The median age at diagnosis is similar in all reports—
fifth decade of life—and ranges between 40.5 and 47 years
(males: 36.5–48.5 and females 38–56) [3, 4, 6, 8, 10, 12].
It is of note that relevant epidemiological data on
gigantism or young-onset acromegaly are sparse and this
is mainly attributed to the rarity of this entity; Daly et al.
[4] and Kwon et al. [14] reported that amongst the
patients with acromegaly identified, 22.2 and 2.4 %,
respectively were aged between 0 and 19 years. In such
cases, and particularly given the recent advances in the
genetics of acromegaly, genetic causes need to be con-
sidered [20].
Presentation and diagnostic delay
The frequency of the presenting manifestations has been
systematically assessed in two population studies (Table 2).
Acral enlargement and coarse facial features are the most
commonly described (78.8–85.7 % and 71.2–71.4 %,
respectively) followed by headaches, macroglossia,
increased sweating, arthralgias, increased skin thickness,
snoring, tiredness and carpal tunnel syndrome [3, 7].
Hoskuldsdottir et al. [7] also looked at the presence of
comorbidities at diagnosis and reported hypertension in
48 %, diabetes mellitus in 13 %, impaired glucose toler-
ance in 19 %, heart failure in 10 % and coronary artery
disease in 8 % of the cases. It should be noted however, that
the reliability of the published information may be affected
by the accuracy of documentation during the history taking
and this needs to be taken into account when reviewing the
frequency of the presenting signs and symptoms.
The duration of symptoms until diagnosis, which may in
a large part be due to diagnostic delay, is still considerable,
Table 3 Duration of symptoms until diagnosis in acromegaly as reported in population studies
Reference Duration of symptoms until diagnosis (years)
Median (range)
Total population Males Females
Fernandez et al. [3] Median 4.5 (range 1.5–15.0) Median 3.0 (range 1.5–15.0) Median 6.0 (range 3.0–15.0)
Daly et al. [4] Median 5 (range 1–25) Median 5.5 (range 1–25) Median 3 (range 1.6–5)
Hoskuldsdottir et al. [7] ‘‘for more than 3 years in most cases’’ NA NA
Mestron et al. [11] ‘‘the patients’ estimates of the year in
which symptoms began was around
5 years before diagnosis’’
NA NA
NA not available
Table 4 Frequency of macro-
and microadenomas in patients
with acromegaly as reported in
population studies
Reference Adenoma size
Macroadenoma (% of cases) Microadenoma (% of cases)
Males Females Males Females
Fernandez et al. [3] 85.7 14.3
Daly et al. [4] 88.9a 0
100 66.7a 0 0a
Tjornstrand et al. [5] 78 77 22 23
Agustsson et al. [6] 62.5 71.4 28.1 23.8
Raappana et al. [8] 78 22
Dal et al. [9] 69 31
Bex et al. [10] 79a 16a
Mestron et al. [11] 69a 25.8a
Gruppetta et al. [12] 73.1 26.9
68.2 76.7 31.8 23.3
Kwon et al. [14] 82.9 17.1
a Percentages do not add up to 100 due to cases with unknown tumor size
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with median estimated intervals of 4.5–5 years; however,
delays of 15 or even 25 years have been reported, in accord
with the insidious onset of symptomatology (Table 3)
[3, 4, 7, 11]. It should be noted though that the actual
duration of the disease is not uniformly collected or
determined and the relevant information, as provided by
the patient, may be subjective and prone to recall bias.
Nonetheless, these data highlight the need for enhancing
the awareness of acromegaly amongst clinicians aiming to
reduce the adverse sequelae of late detection and
management.
At the time of detection, most cases are macroadenomas
([2/3 of cases); this may relate to diagnostic delays and
poses challenges in the surgical management of these
tumors (Table 4) [3–6, 8–12, 14].
Epidemiological data on the prevalence of familial
acromegaly are limited. Bex et al. [10] identified four
patients with MEN1 and two with Familial Isolated Pitu-
itary Adenoma (FIPA)—somatotropinoma in a total of 418
acromegalics giving rates of 0.95 and 0.48 %, respectively.
Mestron et al. [11] found three patients with MEN1 in a
total of 1219 subjects included in the Spanish Acromegaly
Registry (0.25 %).
Conclusions
The rarity of acromegaly necessitates large population
studies for the generation of reliable epidemiological data.
In the last few years, a number of reports based on different
geographical areas and variable health systems have pro-
vided information on the prevalence and incidence of this
condition and suggest 2.8–13.7 cases per 100,000 people
and 0.2–1.1 cases/100,000 people/year, respectively.
Whether these rates may change with the application of
screening of patients with acromegaly-associated condi-
tions remains to be clarified. The diagnostic delay is still
considerable and the disease is usually confirmed in the
fifth decade of life affecting economically active individ-
uals; this translates into loss of productivity, social and
financial consequences and long-term burden on the health
care system, necessitating increased awareness of this
condition in the medical community.
Further areas that remain to be clarified in the epi-
demiology of acromegaly include possible geographical
variations and the impact of other factors (e.g. environ-
mental, ethnic, sex, type of health care system, availability
and access to health care resources), as well as data on
early-onset and familial acromegaly and on mixed GH-
prolactin secreting adenomas. The latter will require ade-
quate powered population collaborative studies which are
eagerly awaited in the future.
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